These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12850663)

  • 1. Is pica in the spectrum of obsessive-compulsive disorders?
    Gundogar D; Demir SB; Eren I
    Gen Hosp Psychiatry; 2003; 25(4):293-4. PubMed ID: 12850663
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obsessive compulsive disorder is not an anxiety disorder.
    Montgomery SA
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():57-62. PubMed ID: 8254154
    [No Abstract]   [Full Text] [Related]  

  • 4. Beyond refractory obsessions and anxiety states: toward remission.
    Hollander E; Zohar J
    J Clin Psychiatry; 2004; 65 Suppl 14():3-5. PubMed ID: 15554781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder.
    Benkert O; Wetzel H; Szegedi A
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():3-14. PubMed ID: 8254151
    [No Abstract]   [Full Text] [Related]  

  • 6. Pica responding to SSRI: an OCD spectrum disorder?
    Bhatia MS; Gupta R
    World J Biol Psychiatry; 2009; 10(4 Pt 3):936-8. PubMed ID: 17853279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Pica an eating disorder or an obsessive-compulsive spectrum disorder?
    Hergüner S; Ozyildirim I; Tanidir C
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):2010-1. PubMed ID: 18848964
    [No Abstract]   [Full Text] [Related]  

  • 8. Venlafaxine in treatment resistant obsessive-compulsive disorder.
    Narayanaswamy JC; Viswanath B; Cherian AV; Math SB; Reddy YC
    J Neuropsychiatry Clin Neurosci; 2014; 26(3):E44-5. PubMed ID: 25093787
    [No Abstract]   [Full Text] [Related]  

  • 9. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obsessive compulsive spectrum disorders.
    Rasmussen SA
    J Clin Psychiatry; 1994 Mar; 55(3):89-91. PubMed ID: 8071254
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
    Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
    J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obsessive-compulsive spectrum disorders.
    Stein DJ; Hollander E
    J Clin Psychiatry; 1995 Jun; 56(6):265-6. PubMed ID: 7775369
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pica and the obsessive-compulsive spectrum disorders.
    Stein DJ; Bouwer C; van Heerden B
    S Afr Med J; 1996 Dec; 86(12 Suppl):1586-8, 1591-2. PubMed ID: 9180801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
    Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
    J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of adherence among patients with obsessive-compulsive disorder undergoing naturalistic pharmacotherapy.
    Santana L; Versiani M; Mendlowicz MV; Fontenelle LF
    J Clin Psychopharmacol; 2010 Feb; 30(1):86-8. PubMed ID: 20075661
    [No Abstract]   [Full Text] [Related]  

  • 17. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R; Dambinsky Y; Timinsky I; Green T; Kotler M; Weizman A; Spivak B
    Int Clin Psychopharmacol; 2013 Mar; 28(2):96-8. PubMed ID: 23211492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The difference between obsessive-compulsive disorder in adolescence and in adults].
    Rabe-Jabłońska J
    Przegl Lek; 2001; 58 Suppl 3():11-4. PubMed ID: 11603169
    [No Abstract]   [Full Text] [Related]  

  • 19. Venlafaxine in obsessive-compulsive disorder.
    Yaryura-Tobias JA; Neziroglu FA
    Arch Gen Psychiatry; 1996 Jul; 53(7):653-4. PubMed ID: 8660133
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Tükel R; Bozkurt O; Polat A; Genç A; Atli H
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):404-9. PubMed ID: 16884439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.